Anthem Biosciences Ltd: Value Pick Stock September 2026
Anthem Biosciences Ltd is a Contract Research, Development, and Manufacturing Organization (CRDMO) and Innovation Service Provider in India.
Anthem Biosciences Ltd: History
The Company was incorporated as Anthem Biosciences Private Limited, a private limited company, under the Companies Act, 1956.
Its name was changed to Anthem Biosciences Limited under a fresh certificate of incorporation issued by the Registrar of Companies (RoC) on December 10, 2024.
ALSO READ: Pranav Constructions IPO Review
Anthem Biosciences Ltd: Business
Anthem Biosciences Ltd is a technology-focused and innovation-driven CRDMO with fully integrated operations spanning –
- Drug Discovery,
- Development, and
- Commercial Manufacturing.
As a one-stop service provider, Anthem_Biosciences serves a range of clients, encompassing innovator-focused emerging biotech and large pharma companies in India and globally.
According to the F&S Report, Anthem is one of the few companies in India with integrated NBE (New Biological Entity) and NCE (New Chemical Entity) capabilities across drug discovery, development & manufacturing.
The company has developed various platforms such as –
- RNA interference (RNAi),
- Antibody-Drug Conjugates (ADCs),
- Lipids,
- Peptides, and
- Oligonucleotides.
According to the F&S Report, Anthem_Biosciences is one of the youngest Indian CRDMO companies and the fastest to achieve a ₹10,000 Cr revenue milestone within 14 years of operations.
In addition to product research and development, the company helps test drugs for –
- Antibody Drug Conjugates,
- Clone Development,
- Efficacy (In Vitro and In Vivo),
- Flow Chemistry Based Production,
- Large Scale Commercial Product Manufacture,
- Pre-Clinical Animal Studies in a GLP Facility,
- R&D and Manufacture of Highly Potent Compounds, and
- Safety.
READ THIS: Prasol Chemicals IPO Review
Manufacturing Facilities
The company has 3 manufacturing facilities, namely,
- Unit I in Bommasandra,
- Unit II in Harohalli, and
- Unit III in Harohalli (under construction)
Client List
The Company serves over 550 clients across 44+ countries, including European countries, the United States, and Japan.
CHECK THIS: Glass Wall Systems IPO Review
Recent Updates
The company has executed over 8,000 unique customer-commissioned programs, collaborating with 675+ clients across multiple stages of drug development within its CRDMO operations.
As of FY25, the company manufactured Active Pharmaceutical Ingredients (APIs) and advanced intermediates for 10 commercialized molecules (all supported from the discovery stage).
Supplied 5 of the top 6 commercialized molecules by revenue for FY25, developed for 3 large pharmaceutical companies.
Ajay Bhardwaj, Chairman, MD and CEO of the company, said –
The underlying demand remains strong, and with a higher concentration of scheduled deliveries in the latter half of the year, we are positioned to capture that momentum.
Listed On
The shares of Anthem Biosciences Ltd. are presently listed on –
- The Bombay Stock Exchange (BSE), CODE 544449, and
- The National Stock Exchange (NSE) as ANTHEM.
Stock Info
Share Holding Pattern
Financial
CONCLUSION
Anthem Biosciences Limited is in the business of providing CRDMO services and manufacturing and selling specialty ingredients.
As of June 2026, the promoters of the company hold more than 71 percent stake in the company.
Along with this, some of the top institutions, such as HDFC Mutual Fund, SBI Mutual Fund, and AXIS Mutual Fund, hold more than 1 percent stake in the company (as of June 2026).
The management remains firmly committed to sustaining revenue growth aligned with its long-term historical performance.
On the technical front, Anthem Biosciences’ share is trading above its 20-day SMA (901) and 200-day SMA (728) on the daily chart.
Considering the above-listed factors in mind, Anthem Biosciences Limited looks good at ₹880 – ₹900.
FinBlab recommends investing in the stock, keeping a long-term (2 to 3 years) view in mind. (One can also accumulate on a decline).
===========================================================================
Disclaimer: This article is purely for informational purposes.
While much time and effort is made to provide the information, I (Vishal Dalwadi) or (FinBlab) do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.
